Delivery Order SPE2DB25D3201-SPE2DB25FNTND
- Not listed
- The Defense Logistics Agency awarded a $37,348.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes, with a completion deadline of November 28, 2025. This non-competitive award, issued on November 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/mL syringes with a ceiling value of $5,568.57. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure with an ultimate completion date of November 13, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a $19,599.47 firm fixed price delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes on December 8, 2025, with a completion date of December 9, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $33,849.19 delivery order for Wezlana 90 mg/ml syringes, with an ultimate completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $15,763.91 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes, with a completion date of September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the place of performance in Conshohocken, PA. This delivery order represents a task order under AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a $5,568.57 delivery order for Wezlana 90 mg/ml syringes, with an ultimate completion date of September 19, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract awarded under AmerisourceBergen's larger indefinite delivery contract (IDC) vehicle with DLA Troop Support...
- The Defense Logistics Agency awarded a $71,048.38 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Wezlana 90 mg/mL syringes. The contract utilizes firm fixed pricing and carries an ultimate completion date of June 20, 2025. This competitively awarded delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract...
- The Defense Logistics Agency awarded a $7,146.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes, with an ultimate completion date of December 3, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $74,758.45 by the Defense Logistics Agency on August 14, 2025, for the supply of Wezlana 90 mg/mL syringes. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 15, 2025, and will be performed at the contractor's Conshohocken facility. The award represents a child delivery order issued under...
- The Defense Logistics Agency awarded a $30,488.88 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes. The contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed price pricing with no set-aside designation. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNTNDDelivery Order
The Defense Logistics Agency awarded a $48,728.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes, with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. AmerisourceBergen Drug Corp serves as a critical vendor in the federal medical supply chain, providing pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver diverse medical commodities, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic areas. This award reflects the company's continued role as a primary pharmaceutical supplier for the Defense Health Agency and other federal healthcare systems under DLA's comprehensive medical supply vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.7k | 5/30/25 |